RxDoctor Payments Data

Elizabeth Scheidler, APRN

Family · Kuttawa, KYNPI 1467776716

Payments from drug & device makers

$4,876in general payments, 2019–2025

Across 178 payments — averaging $27.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$2K
  • AbbVie$707
  • AstraZeneca$452
  • Novo Nordisk$415
  • Otsuka America Pharmaceutical, Inc.$386
  • Lilly USA, LLC$149
  • plus $1K from 24 others

What the payments were for

  • Travel & lodging$1,22325%
  • Food & beverage$3,55473%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,876 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,573
Medicare patients
47
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$119,911
EliquisApixaban37$43,801
OzempicSemaglutide29$40,317
TrulicityDulaglutide27$37,232
FarxigaDapagliflozin Propanediol57$36,466
UbrelvyUbrogepant19$30,712
JardianceEmpagliflozin36$26,504
QuliptaAtogepant17$24,072
LinzessLinaclotide31$22,518
XareltoRivaroxaban15$15,855
JanuviaSitagliptin Phosphate16$15,404
Repatha SureclickEvolocumab19$13,601
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$9,150
Combivent RespimatIpratropium/Albuterol Sulfate13$6,604
Desvenlafaxine Succinate ErDesvenlafaxine Succinate69$5,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$149$157,143107 claims
AbbVieUbrelvy, Qulipta, Linzess, Synthroid$707$78,35684 claims
AstraZenecaFarxiga, Breztri Aerosphere$452$45,61573 claims
PfizerEliquis$123$43,80137 claims
Novo NordiskOzempic$415$40,31729 claims
Boehringer IngelheimJardiance, Combivent Respimat$12$33,10749 claims
MerckJanuvia$17$15,40416 claims
Astellas Pharma US IncMyrbetriq$127$5,27512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Kuttawa

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →